TrialLancet (London, England)2019

Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.

Hisham Mehanna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.